Descriptive epidemiology of primary malignant and non-malignant central nervous tumors in Spain: Results from the Girona Cancer Registry (1994–2013)

• Published in: Cancer epidemiology Vol. 50; no. Pt A; pp. 1 - 8
• Main Authors: Fuentes-Raspall, Rafael, Solans, Marta, Roca-Barceló, Aina, Vilardell, Loreto, Puigdemont, Montse, del Barco, Sonia, Comas, Raquel, García-Velasco, Adelaida, Astudillo, Aurora, Carmona-Garcia, Mª Carme, Marcos-Gragera, Rafael
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.10.2017; Elsevier Limited
• Subjects: Age; Brain cancer; Cancer; Central nervous system; Classification; Epidemiology; Incidence; Mortality; Nervous system; Non-malignant; Pediatrics; Population; Population-based; Primary central nervous tumors; Radiation therapy; Registration; Spain; Survival; Survival analysis; Trends; Tumors; Womens health; United States > US; Europe; Spain; RS; OS; IRUS; CBTRUS; IR; MV; Non-malignant; Survival; CR; IRW; EAPC; Primary central nervous tumors; Incidence; Spain; DCO; Population-based; GCR
• ISSN: 1877-7821; 1877-783X
• DOI: 10.1016/j.canep.2017.07.005

•Non-malignant CNS tumors are not systematically registered in Europe.•The proportion of non-malignant cases was 49.8%, similar to malignant tumors.•Survival is still dramatically associated to both age and histological subtype.•First study assessing incidence and survival of CNS non-malignant tumors in Spain. Systematic registration of non-malignant central nervous system (CNS) tumors is a rare practice among European cancer registries. Thus, the real burden of all CNS tumors across Europe is underestimated. The Girona Cancer Registry provides here the first data on CNS tumor incidence and survival trends in Spain for all histological types, including malignant and non-malignant tumors. Data on all incident cases of primary CNS tumors notified to the Girona population-based cancer registry from 1994 to 2013 (n=2,131) were reviewed. Incidences rates (IRs) were standardized to the 2013 European population and annual percentage changes (EAPC) were estimated using a piecewise log linear model. 1- and 5-year observed (OS) and relative survival (RS) were also calculated. Results were expressed by sex, age-group, histological subtype and behavior. The overall IR was 16.85 and increased across the period of study (EAPC=+2.2%). The proportion and IRs of malignant (50.2%; IR=9.35) and non-malignant cases (49.8%; IR=9.14) were similar; however, non-malignant tumors were more frequent in women (sex ratio=0.63). The most frequently reported histologies were meningioma (27.6%; IR=5.11) and glioblastoma (22.2%; IR=4.15), which also accounted for the highest and lowest 5-year RS (80.2%; 3.7%, respectively). Globally, 5-year RS was lower in men (42.6% vs. 58.3%, respectively) and in the elderly (64.9% for 0–14years vs. 23.0% for >74years). This study presents a comprehensive overview of the epidemiology of malignant and non-malignant CNS primary tumors from the well-established region-wide Girona Cancer Registry (1994–2013). Incidence rates were recovered for all histologies. Survival is still dramatically associated to both age and histological subtype.